Safety and efficacy of iStent Inject trabecular micro-bypass stents in combination with phacoemulsification for chronic open angle glaucoma associated with cataract

被引:0
|
作者
Cela, D. [1 ,2 ]
Brasnu, E. [1 ,2 ]
Hamard, P. [1 ,2 ]
Baudouin, C. [1 ,2 ,3 ]
Labbe, A. [1 ,2 ,3 ]
机构
[1] Quinze Vingts Natl Ophthalmol Hosp, Dept Ophthalmol 3, INSERM, IHU Foresight,DGOS C 1423, 28 Rue Charenton, F-75012 Paris, France
[2] Sorbonne Univ, CNRS, INSERM, Inst Vis,IHU Foresight, Paris, France
[3] Univ Versailles St Quentin Yvelines, Ambroise Pare Hosp, AP HP, Dept Ophthalmol,IHU Foresight, Boulogne Billancourt, France
来源
JOURNAL FRANCAIS D OPHTALMOLOGIE | 2023年 / 46卷 / 02期
关键词
Minimally invasive; glaucoma surgery; Open-angle; Trabecular stent; Phacoemulsification; ONE-YEAR OUTCOMES; INTRAOCULAR-PRESSURE; IMPLANTATION; SURGERY; EXTRACTION;
D O I
10.1016/j.jfo.2022.08.007
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background. - The goal of this study was to assess the efficacy and safety of phacoemulsification combined with iStent Inject((R)) implantation for the treatment of chronic open-angle glaucoma controlled on topical anti-glaucoma medications and associated with cataract. Methods. - This study was a retrospective analysis of patients who underwent phacoemulsification and implantation of an iStent Inject((R)) for chronic open-angle glaucoma associated with cataract. For all patients, pre- and postoperative characteristics, including number of glaucoma medications and intraocular pressure (IOP), were compared using Paired-sample t-tests and Wilcoxon signed-rank tests, respectively. Postoperative visits were scheduled at 7 days and 1, 3, 6, and 12 months after surgery. Results. - Forty-nine eyes of 39 patients were included in the study. Mean preoperative IOP at baseline was 16.3 +/- 4.3 mmHg (range, 10-29 mmHg) with a mean of 2.2 +/- 1.0 mmHg antiglaucoma medications. At 1 month, the mean IOP reduction was 16% (P < 0.05) along with an 18.7% reduction in the mean number of medications. At 6 months, the mean IOP was 12.8 +/- 2.6, witha mean of 1.1 +/- 0.9 antiglaucoma medications. The mean IOP reduction at 6 months was 22% (P < 0.05) along with a 49% reduction in the mean number of medications. At 12 months, themean IOP was 13.8 +/- 2.5 with a mean of 1.1 +/- 1.2 medications. The mean IOP reduction at 12 months was 15% (P < 0.05) along with a 47% reduction in the mean number of medications. No severe device-related side effects were observed. Conclusions. - iStent Inject((R)) implantation combined with phacoemulsification resulted ineffective IOP reduction and medication burden in patients with mild to advanced chronic open-angle glaucoma and preoperative IOP well controlled with topical hypotensive medications. (c) 2023 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:129 / 136
页数:8
相关论文
共 50 条
  • [21] Ab interno trabecular bypass surgery with iStent® and iStent inject® for open angle glaucoma
    Neo, Yan Ning
    Panos, Georgios D.
    Gatzioufas, Zisis
    Vergados, Athanasios
    THERAPEUTIC DELIVERY, 2020, 11 (06) : 357 - 362
  • [22] Effectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma
    Sarkisian, Steven R., Jr.
    Grover, Davinder S.
    Gallardo, Mark J.
    Brubaker, Jacob W.
    Giamporcaro, Jane Ellen
    Hornbeak, Dana M.
    Katz, L. Jay
    Navratil, Tomas
    JOURNAL OF GLAUCOMA, 2023, 32 (01) : 9 - 18
  • [23] Standalone Implantation of 2–3 Trabecular Micro-Bypass Stents (iStent inject ± iStent) as an Alternative to Trabeculectomy for Moderate-to-Severe Glaucoma
    Ricardo Augusto Paletta Guedes
    Daniela Marcelo Gravina
    Vanessa Maria Paletta Guedes
    Alfredo Chaoubah
    Ophthalmology and Therapy, 2022, 11 : 271 - 292
  • [24] 7-Year Efficacy and Safety of iStent inject Trabecular Micro-Bypass in Combined and Standalone Usage
    Hengerer, Fritz H.
    Auffarth, Gerd U.
    Conrad-Hengerer, Ina
    ADVANCES IN THERAPY, 2024, 41 (04) : 1462 - 1480
  • [25] 7-Year Efficacy and Safety of iStent inject Trabecular Micro-Bypass in Combined and Standalone Usage
    Fritz H. Hengerer
    Gerd U. Auffarth
    Ina Conrad-Hengerer
    Advances in Therapy, 2024, 41 : 1481 - 1495
  • [26] Mid-term evaluation of the safety and efficacy of the iStent trabecular micro-bypass system combined with phacoemulsification
    Kozera, Milena
    Konopinska, Joanna
    Rekas, Marek
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2021, 30 (01): : 49 - 54
  • [27] iStent inject Trabecular Micro-Bypass with or Without Cataract Surgery Yields Sustained 5-Year Glaucoma Control
    Hengerer, Fritz H.
    Auffarth, Gerd U.
    Conrad-Hengerer, Ina
    ADVANCES IN THERAPY, 2022, 39 (03) : 1417 - 1431
  • [28] EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS
    Samuelson, T.
    Singh, I. P.
    Katz, L. J.
    Falvey, H.
    Odom, D.
    McSorley, D.
    VALUE IN HEALTH, 2019, 22 : S890 - S890
  • [29] iStent inject Trabecular Micro-Bypass with or Without Cataract Surgery Yields Sustained 5-Year Glaucoma Control
    Fritz H. Hengerer
    Gerd U. Auffarth
    Ina Conrad-Hengerer
    Advances in Therapy, 2022, 39 : 1417 - 1431
  • [30] A review of the iStent (R) trabecular micro-bypass stent: safety and efficacy
    Wellik, Sarah R.
    Dale, Elizabeth A.
    CLINICAL OPHTHALMOLOGY, 2015, 9 : 677 - 684